X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA FDC LTD. NATCO PHARMA/
FDC LTD.
 
P/E (TTM) x 16.0 23.4 68.1% View Chart
P/BV x 17.2 5.3 326.6% View Chart
Dividend Yield % 0.7 0.9 74.0%  

Financials

 NATCO PHARMA   FDC LTD.
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
FDC LTD.
Mar-14
NATCO PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs877144 611.1%   
Low Rs42479 536.1%   
Sales per share (Unadj.) Rs223.447.6 469.7%  
Earnings per share (Unadj.) Rs31.17.6 408.3%  
Cash flow per share (Unadj.) Rs40.39.0 447.0%  
Dividends per share (Unadj.) Rs5.002.25 222.2%  
Dividend yield (eoy) %0.82.0 38.0%  
Book value per share (Unadj.) Rs219.547.5 461.8%  
Shares outstanding (eoy) m33.07177.83 18.6%   
Bonus/Rights/Conversions PABB-  
Price / Sales ratio x2.92.3 124.4%   
Avg P/E ratio x20.914.6 143.2%  
P/CF ratio (eoy) x16.112.3 130.8%  
Price / Book Value ratio x3.02.3 126.6%  
Dividend payout %16.129.6 54.4%   
Avg Mkt Cap Rs m21,50419,784 108.7%   
No. of employees `000NANA-   
Total wages/salary Rs m1,1281,221 92.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m7,3898,459 87.4%  
Other income Rs m167394 42.5%   
Total revenues Rs m7,5568,852 85.4%   
Gross profit Rs m1,7932,070 86.6%  
Depreciation Rs m304249 122.2%   
Interest Rs m36631 1,180.9%   
Profit before tax Rs m1,2902,184 59.1%   
Minority Interest Rs m460-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309606 51.0%   
Profit after tax Rs m1,0271,353 75.9%  
Gross profit margin %24.324.5 99.2%  
Effective tax rate %23.927.7 86.3%   
Net profit margin %13.916.0 86.9%  
BALANCE SHEET DATA
Current assets Rs m3,6814,355 84.5%   
Current liabilities Rs m3,1231,792 174.3%   
Net working cap to sales %7.630.3 24.9%  
Current ratio x1.22.4 48.5%  
Inventory Days Days8944 201.3%  
Debtors Days Days5925 237.9%  
Net fixed assets Rs m7,6853,025 254.1%   
Share capital Rs m331179 185.2%   
"Free" reserves Rs m6,6708,243 80.9%   
Net worth Rs m7,2598,453 85.9%   
Long term debt Rs m95511 8,924.3%   
Total assets Rs m11,95710,557 113.3%  
Interest coverage x4.571.4 6.3%   
Debt to equity ratio x0.10 10,392.5%  
Sales to assets ratio x0.60.8 77.1%   
Return on assets %11.713.1 88.9%  
Return on equity %14.216.0 88.4%  
Return on capital %20.723.5 88.2%  
Exports to sales %39.413.3 295.7%   
Imports to sales %5.73.3 170.5%   
Exports (fob) Rs m2,9081,126 258.3%   
Imports (cif) Rs m421283 148.9%   
Fx inflow Rs m3,4451,146 300.6%   
Fx outflow Rs m703355 197.8%   
Net fx Rs m2,743791 346.8%   
CASH FLOW
From Operations Rs m1,4401,485 97.0%  
From Investments Rs m-1,089-620 175.8%  
From Financial Activity Rs m-353-753 46.9%  
Net Cashflow Rs m-1113 -1.3%  

Share Holding

Indian Promoters % 52.0 68.9 75.5%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 4.7 166.8%  
FIIs % 16.6 7.5 221.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 19.0 136.8%  
Shareholders   25,395 23,730 107.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   PFIZER  GSK PHARMA  PLETHICO PHARMA  WYETH LTD  ABBOTT INDIA  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

FDC LTD. Announces Quarterly Results (1QFY19); Net Profit Up 74.5% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, FDC LTD. has posted a net profit of Rs 511 m (up 74.5% YoY). Sales on the other hand came in at Rs 3 bn (up 16.7% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 17, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - SANOFI INDIA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS